Company intelligence / Profile preview

IDBiologics

Nashville, Tennessee, United Statesidbiologics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company has 6 clinical lead candidate molecules with robust animal proof of concept. Currently developing a two-antibody medicine against Rift Valley fever virus through preclinical development and Phase 1 clinical studies.

Therapeutic areas: Infectious Diseases
Modalities: Monoclonal antibodies (mAbs)
Industry: Biotech

Drug pipeline

10 assets

IDB-011

9 more assets in the full pipeline.

Request access →

Partnerships

United States Department of DefenseVanderbilt University Medical CenterGlobal Pandemic Prevention and Biodefense Center

Beyond the preview

Go deeper on IDBiologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDBiologics.

Explore the full profile